HC Wainwright Analysts Raise Earnings Estimates for CANF

Can-Fite BioPharma Ltd. (NYSE:CANF) – Research analysts at HC Wainwright lifted their Q3 2024 earnings per share estimates for Can-Fite BioPharma in a report released on Tuesday, November 12th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($0.27) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.25) EPS and FY2025 earnings at ($0.05) EPS.

Separately, StockNews.com upgraded shares of Can-Fite BioPharma from a “sell” rating to a “hold” rating in a research report on Tuesday.

Can-Fite BioPharma Trading Down 3.4 %

NYSE CANF opened at $2.00 on Thursday. Can-Fite BioPharma has a 1-year low of $1.83 and a 1-year high of $4.69. The stock’s 50 day moving average is $2.26 and its two-hundred day moving average is $2.52. The company has a market capitalization of $7.08 million, a price-to-earnings ratio of -1.11 and a beta of 1.39.

Institutional Investors Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC grew its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.